Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 08 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E15.72 EPS (ttm)0.89 Insider Own17.83% Shs Outstand105.65M Perf Week1.88%
Market Cap1.50B Forward P/E- EPS next Y-1.07 Insider Trans0.00% Shs Float87.57M Perf Month7.99%
Income96.55M PEG- EPS next Q-0.28 Inst Own61.60% Short Float / Ratio4.19% / 1.34 Perf Quarter79.11%
Sales243.69M P/S6.15 EPS this Y-189.91% Inst Trans25.38% Short Interest3.67M Perf Half Y37.30%
Book/sh4.01 P/B3.51 EPS next Y-16.14% ROA24.04% Target Price14.31 Perf Year109.85%
Cash/sh3.18 P/C4.42 EPS next 5Y- ROE26.33% 52W Range6.39 - 14.00 Perf YTD92.87%
Dividend- P/FCF16.16 EPS past 5Y- ROI22.30% 52W High0.43% Beta-0.00
Dividend %- Quick Ratio9.14 Sales past 5Y0.00% Gross Margin98.93% 52W Low120.03% ATR0.32
Employees129 Current Ratio9.14 Sales Q/Q- Oper. Margin44.23% RSI (14)74.14 Volatility2.15% 2.59%
OptionableYes Debt/Eq0.03 EPS Q/Q9.89% Profit Margin39.62% Rel Volume0.57 Prev Close13.95
ShortableYes LT Debt/Eq0.02 EarningsNov 13 BMO Payout0.00% Avg Volume2.75M Price14.06
Recom2.60 SMA203.37% SMA5010.90% SMA20048.77% Volume1,566,647 Change0.79%
Date Action Analyst Rating Change Price Target Change
Jul-20-23Resumed Jefferies Buy $12 → $14
Dec-14-22Initiated Raymond James Outperform $10
Nov-30-22Initiated SVB Leerink Outperform $14
Oct-11-22Initiated Oppenheimer Outperform $20
Sep-16-22Initiated Truist Buy $22
Sep-14-22Initiated Berenberg Buy $20
Aug-16-22Initiated Guggenheim Buy $20
Jul-06-22Initiated William Blair Outperform
May-26-22Upgrade Jefferies Hold → Buy $7 → $20
Jul-29-21Initiated Cowen Outperform
Dec-05-23 01:11PM
Dec-04-23 06:45AM
Nov-29-23 10:45AM
Nov-22-23 10:17AM
Nov-17-23 06:45AM
04:33PM Loading…
Nov-14-23 04:33PM
Nov-13-23 07:30AM
Nov-08-23 04:56PM
Oct-26-23 12:29PM
Oct-13-23 02:56PM
Oct-10-23 10:22AM
Oct-03-23 04:22PM
06:45AM Loading…
Sep-18-23 08:00AM
Aug-14-23 07:30AM
Jul-31-23 09:00AM
Jun-26-23 07:45AM
Jun-12-23 08:00AM
Jun-07-23 07:00AM
May-25-23 08:30AM
May-15-23 07:35AM
Apr-24-23 07:30AM
Apr-04-23 08:00AM
Mar-27-23 08:00AM
Mar-07-23 07:45AM
08:30AM Loading…
Feb-02-23 08:30AM
Jan-12-23 08:30AM
Dec-20-22 08:30AM
Nov-29-22 07:30AM
Nov-14-22 07:15AM
Oct-17-22 08:30AM
Sep-16-22 04:30PM
Sep-13-22 09:47PM
Sep-10-22 03:05AM
Sep-04-22 06:10PM
Aug-18-22 04:30PM
Aug-12-22 08:30AM
Aug-08-22 08:30AM
Jul-06-22 08:30AM
Jun-21-22 08:30AM
May-19-22 05:30PM
May-16-22 08:30AM
May-13-22 08:30AM
May-05-22 09:15AM
Apr-26-22 08:30AM
Apr-11-22 04:30PM
Mar-30-22 12:40PM
Mar-25-22 08:30AM
Mar-22-22 08:30AM
Mar-15-22 04:30PM
Feb-25-22 09:00AM
Feb-17-22 08:30AM
Feb-14-22 08:30AM
Feb-01-22 08:30AM
Jan-24-22 05:38PM
Jan-04-22 08:30AM
Dec-01-21 08:30AM
Nov-24-21 08:30AM
Nov-22-21 08:30AM
Nov-12-21 08:30AM
Nov-09-21 08:30AM
Oct-29-21 08:30AM
Sep-28-21 08:00AM
Sep-23-21 08:00AM
Sep-14-21 07:33AM
Sep-08-21 08:30AM
Sep-07-21 08:00AM
Aug-13-21 07:06AM
Aug-10-21 04:01PM
POINT Biopharma Global, Inc. is a radiopharmaceutical company. It engages in the business of building a platform for the clinical development and commercialization of radioligands that fight cancer. The company was founded by Joe McCann and Neil E. Fleshner on April 15, 2020 and is headquartered in Indianapolis, IN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HOGUE GERALD L.DirectorMar 21Option Exercise6.9717,936125,01421,596Mar 23 08:09 PM